CHF92.92
0.01% yesterday
SIX Swiss Exchange, May 06, 05:30 pm CET
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Novartis Stock price

CHF92.92
+5.80 6.66% 1M
-0.84 0.90% 6M
+4.22 4.76% YTD
+4.82 5.47% 1Y
+13.68 17.27% 3Y
+14.66 18.73% 5Y
+15.70 20.32% 10Y
SIX Swiss Exchange, Closing price Tue, May 06 2025
-0.01 0.01%
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Key metrics

Market capitalization CHF176.32b
Enterprise Value CHF197.70b
P/E (TTM) P/E ratio 16.28
EV/FCF (TTM) EV/FCF 12.69
EV/Sales (TTM) EV/Sales 4.31
P/S ratio (TTM) P/S ratio 3.84
P/B ratio (TTM) P/B ratio 5.36
Dividend yield 3.77%
Last dividend (FY24) CHF3.50
Revenue growth (TTM) Revenue growth 6.34%
Revenue (TTM) Revenue CHF45.86b
EBIT (operating result TTM) EBIT CHF14.51b
Free Cash Flow (TTM) Free Cash Flow CHF15.58b
Cash position CHF6.37b
EPS (TTM) EPS CHF5.71
P/E forward 16.56
P/S forward 3.94
EV/Sales forward 4.42
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Novartis forecast:

4x Buy
15%
18x Hold
69%
4x Sell
15%

Analyst Opinions

26 Analysts have issued a Novartis forecast:

Buy
15%
Hold
69%
Sell
15%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
45,864 45,864
6% 6%
100%
- Direct Costs 11,713 11,713
3% 3%
26%
34,152 34,152
10% 10%
74%
- Selling and Administrative Expenses 6,116 6,116
32% 32%
13%
- Research and Development Expense 8,305 8,305
8% 8%
18%
19,730 19,730
5% 5%
43%
- Depreciation and Amortization 5,216 5,216
25% 25%
11%
EBIT (Operating Income) EBIT 14,514 14,514
23% 23%
32%
Net Profit 11,413 11,413
16% 16%
25%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

AD HOC NEWS
8 days ago
Novartis CH0012005267 stärkt seine Pipeline im Bereich Nierenerkrankungen mit der Übernahme von Regulus Therapeutics.
AD HOC NEWS
9 days ago
Das Analysehaus Jefferies hat die Einstufung für Novartis CH0012005267 auf "Hold" mit einem Kursziel von 100 Franken belassen.
AD HOC NEWS
9 days ago
Dem Pharmakonzern Novartis CH0012005267 ist einmal mehr eine positive Überraschung gelungen: In den ersten drei Monaten haben die Basler nicht nur besser als erwartet abgeschnitten, auch für den weiteren Geschäftsverlauf zeigt sich das Management laut Mitteilung vom Dienstag nochmals zuversichtlicher als bisher.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today